| Abstract: | Datamonitor's MGI Pharma Inc - SWOT Analysis company profile is the essential source for top-level company data and information. MGI Pharma Inc - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
MGI Pharma is a biopharmaceutical company that acquires, researches, develops and commercializes proprietary pharmaceutical products. The company's therapeutic emphasis is on the areas of oncology and acute care. The company markets cancer and acute care related pharmaceutical products such as Aloxi, Dacogen, Gliadel Wafer, Salagen and Hexalen in the US. MGI Pharma is headquartered in Bloomington, Minnesota and employed 540 people as of December 2006. The company recorded revenues of $343 million during the fiscal year ended December 2006, an increase of 22.7% over 2005. The operating loss of the company was $31 million during fiscal year 2006, as compared to an operating loss of $135 million in the year 2005. The net loss was $40 million in fiscal year 2006, as compared to a net loss of $132 million in the year 2005.
Scope of the Report
- Provides all the crucial information on MGI Pharma Inc required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting MGI Pharma Inc in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of MGI Pharma Inc
-Data is supplemented with details on MGI Pharma Inc history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from MGI Pharma Inc
Reasons to Purchase
- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available
|
| Brief Excerpt: | ...MGI Pharma is a biopharmaceutical company that acquires, researches, develops and commercializes proprietary pharmaceutical products.The company's therapeutic emphasis is on the areas of oncology and acute care. The company markets cancer and acute care related pharmaceutical products such as Aloxi, Dacogen, Gliadel Wafer, Salagen and Hexalen in the US. MGI Pharma is headquartered in Bloomington, Minnesota and employed 540 people as of December 2006. The company recorded revenues of $343 million during the fiscal year ended December 2006, an increase of 22.7% over 2005. The operating loss of the company was $31 million during fiscal year 2006, as compared to an operating loss of $135 million in the year 2005. The net loss was $40 million in fiscal year 2006, as compared to a net loss of $132 million in the year 2005....
|
